Pain — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for pain. 144 active patents protecting 6 drugs from 6+ originators. First major cliff: 2032. Daily refresh.

6
Approved drugs
144
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Pain

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson (Janssen Pharmaceutica) 68 patents Pfizer 24 patents Fresenius Kabi 14 patents Hisamitsu Pharmaceutical Co., Inc 14 patents Generic (originally Boots Group) 14 patents Baxter 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating pain. Each bar = one year. Y-axis scaled to peak year (66 patents).

66
27
3
28
17
29
32
30
11
32
4
33
10
34
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Duragesic
fentanyl
 Johnson & Johnson (Janssen Pharmaceutica) 68 51 — 2027-01-25
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Dilaudid-Hp
Hydromorphone Hydrochloride
 Fresenius Kabi 14 46 — 2032-04-23
Advil
ibuprofen
 Generic (originally Boots Group) 14 70 — 2029-09-30
Renacidin
CITRIC ACID
 Baxter 10 56 — 2028-10-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8946292 Arthrotec method of use 80 2027-03-22
8871809 Arthrotec method of use 80 2027-10-17
8563613 Arthrotec method of use 80 2027-10-17
8252838 Arthrotec method of use 80 2028-04-21
11806400 Advil method of use 76 2032-03-16
11806400 Advil method of use 76 2032-03-16
9168305 Arthrotec method of use 75 2027-10-17
9220784 Arthrotec method of use 75 2027-10-17
9132110 Arthrotec method of use 75 2027-10-17
9339551 Arthrotec method of use 75 2027-10-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11439610 Renacidin composition of matter 12 2033-03-15
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
10624879 Renacidin formulation 42 2034-06-23
9248229 Dilaudid-Hp formulation 42 2034-03-12

Related